This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


User:Kiera Malone/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
-
<scene name='90/909366/Color/2'>ATAD2B</scene> is an understudied protein, and therefore very little is known about its overall function. It is a nuclear protein that is a highly sequentially and structurally conserved paralog to ATAD2<ref>PMID:21158754</ref>. It is unknown when the gene duplication event occurred that was able to form both ATAD2 and ATAD2B proteins in evolutionary history, or how ATAD2 and ATA2B interact with each other within a cellular context. ATAD2 is a nuclear co-regulator protein and found to be highly overexpressed in many unrelated forms of cancer<ref>PMID:20581866</ref><ref>PMID:20864510</ref>. ATAD2 overexpression is linked to poor prognosis in these cancer patients. In cancer cell proliferation, ATAD2 is a direct target of E2F, a member of the frequently mutated retinoblastoma protein pathway(2). ATAD2 also acts as a cofactor for the ''Myc'' oncogene, and is engaged in a positive feedback loop to continually amplify the expression of itself and other coregulators in cancer(2). The overall biological function of ATAD2 has yet to be elucidated, but has been implicated in stimulating gene expression, promoting chromatin remodeling, and impacting DNA repair. On the other hand, ATAD2B has not been characterized nearly as much as ATAD2, but it is thought to be involved in neuronal development, and was found overexpresed in multiple human tumors (Leachman, lloyd).
+
<scene name='90/909366/Color/2'>ATAD2B</scene> is an understudied protein, and therefore very little is known about its overall function. It is a nuclear protein that is a highly sequentially and structurally conserved paralog to ATAD2<ref>PMID:21158754</ref>. It is unknown when the gene duplication event occurred that was able to form both ATAD2 and ATAD2B proteins in evolutionary history, or how ATAD2 and ATA2B interact with each other within a cellular context. ATAD2 is a nuclear co-regulator protein and found to be highly overexpressed in many unrelated forms of cancer<ref>PMID:20581866</ref><ref>PMID:20864510</ref>. ATAD2 overexpression is linked to poor prognosis in these cancer patients. In cancer cell proliferation, ATAD2 is a direct target of E2F, a member of the frequently mutated retinoblastoma protein pathway<ref>PMID:19843847</ref>. ATAD2 also acts as a cofactor for the ''Myc'' oncogene, and is engaged in a positive feedback loop to continually amplify the expression of itself and other coregulators in cancer<ref>PMID:19843847</ref>. The overall biological function of ATAD2 has yet to be elucidated, but has been implicated in stimulating gene expression, promoting chromatin remodeling, and impacting DNA repair. On the other hand, ATAD2B has not been characterized nearly as much as ATAD2, but it is thought to be involved in neuronal development, and was found overexpresed in multiple human tumors<ref>PMID:21158754</ref><ref>PMID:33084328</ref>.
===Structural Organization===
===Structural Organization===
[[Image:4proteopediadomains.png|thumb|right|300px|ATAD2B Domains]]
[[Image:4proteopediadomains.png|thumb|right|300px|ATAD2B Domains]]
Both the ATAD2 and ATAD2B proteins contain two conserved domains: an ''AAA <font color='gold'>ATPase</font> domain'' and a ''<font color='gray'>bromodomain</font>''<ref>PMID:22464331</ref>. The ''<font color='gold'>ATPase</font> domains'' are associated with diverse cellular activities and are thought to play a role in ATAD2 oligomerization, and is suspected to act as a molecular motor involved in chromatin remodeling. ''<font color='gray'>Bromodomains</font>'' "read" or interpret the epigenetic acetylated lysine post-translational modification (PTM)<ref>PMID:17694091</ref>.
Both the ATAD2 and ATAD2B proteins contain two conserved domains: an ''AAA <font color='gold'>ATPase</font> domain'' and a ''<font color='gray'>bromodomain</font>''<ref>PMID:22464331</ref>. The ''<font color='gold'>ATPase</font> domains'' are associated with diverse cellular activities and are thought to play a role in ATAD2 oligomerization, and is suspected to act as a molecular motor involved in chromatin remodeling. ''<font color='gray'>Bromodomains</font>'' "read" or interpret the epigenetic acetylated lysine post-translational modification (PTM)<ref>PMID:17694091</ref>.
-
Investigators who study ATAD2 and ATAD2B focus on their <font color='gray'>bromodomains</font>, because they can be targeted pharmaceutically for disease therapy. The structure and function of the '''ATAD2''' <font color='gray'>bromodomain</font> has been well characterized<ref>PMID:34502039</ref> . The binding function of the '''ATAD2B''' <font color='gray'>bromodomain</font> has begun to be characterized<ref>PMID:33084328</ref>. While there are over 100 '''ATAD2''' <font color='gray'>bromodomain</font> structures in the PDB, and some other domains have been characterized in yeast homologs(CHO), the <font color='gray'>bromodomain</font> is the only domain to be studied ''or'' characterized structurally, with only three structures in the PDB for '''ATAD2B'''.
+
Investigators who study ATAD2 and ATAD2B focus on their <font color='gray'>bromodomains</font>, because they can be targeted pharmaceutically for disease therapy. The structure and function of the '''ATAD2''' <font color='gray'>bromodomain</font> has been well characterized<ref>PMID:34502039</ref> . The binding function of the '''ATAD2B''' <font color='gray'>bromodomain</font> has begun to be characterized<ref>PMID:33084328</ref>. While there are over 100 '''ATAD2''' <font color='gray'>bromodomain</font> structures in the PDB, and some other domains have been characterized in yeast homologs<ref>PMID:31848341</ref>, the <font color='gray'>bromodomain</font> is the only domain to be studied ''or'' characterized structurally, with only three structures in the PDB for '''ATAD2B'''.
'''Although ATAD2 and ATAD2B are highly conserved, there is very little known about the function of ATAD2B, about the function of its domains, or its role in oncogenesis.'''
'''Although ATAD2 and ATAD2B are highly conserved, there is very little known about the function of ATAD2B, about the function of its domains, or its role in oncogenesis.'''
Line 24: Line 24:
'''Role of histone post-translational modifications (PTMs)'''
'''Role of histone post-translational modifications (PTMs)'''
-
Epigenetics is the study of the molecules or mechanisms that cause changes in gene expression, without any modification to the underlying DNA sequence. DNA methylation, long non-coding RNAs, and post-translational modifications (PTMs) are all areas of epigenetic study (waddington).
+
Epigenetics is the study of the molecules or mechanisms that cause changes in gene expression, without any modification to the underlying DNA sequence. DNA methylation, long non-coding RNAs, and post-translational modifications (PTMs) are all areas of epigenetic study <ref>PMID:10521337</ref>.
[[Image:Higherorderchromatin.png|thumb|right|200px|Visual illustrating the NCP compacting DNA into higher order chromatin structure.]]
[[Image:Higherorderchromatin.png|thumb|right|200px|Visual illustrating the NCP compacting DNA into higher order chromatin structure.]]
-
PTMs can occur on the histone proteins that compose the <scene name='90/909366/Ncp/1'>nucleosome core particle</scene> (NCP). The NCP is the fundamental unit of chromatin and impacts gene accessibility to transcriptional regulators. Histones are positively charged and work to compact the negatively charged DNA around an octamer of histone proteins. Multiple NCPs compact DNA to form higher order chromatin structure, all the way to the level of the chromosome(CAVALLI). Additionally, there are unstructured extensions at the N-terminus of histone proteins, termed <scene name='90/909366/Ncp/2'>tails</scene>, which are also positively charged. This compact histone octamer wrapped with DNA becomes the nucleosome core particle (NCP), the fundamental unit of chromatin, which poses a barrier to transcription (strahl)(luger).
+
PTMs can occur on the histone proteins that compose the <scene name='90/909366/Ncp/1'>nucleosome core particle</scene> (NCP). The NCP is the fundamental unit of chromatin and impacts gene accessibility to transcriptional regulators. Histones are positively charged and work to compact the negatively charged DNA around an octamer of histone proteins. Multiple NCPs compact DNA to form higher order chromatin structure, all the way to the level of the chromosome<ref>PMID:31341302</ref>. Additionally, there are unstructured extensions at the N-terminus of histone proteins, termed <scene name='90/909366/Ncp/2'>tails</scene>, which are also positively charged. This compact histone octamer wrapped with DNA becomes the nucleosome core particle (NCP), the fundamental unit of chromatin, which poses a barrier to transcription<ref>PMID:10638745</ref><ref>PMID:9305837</ref>.
[[Image:Postptms.png|center|600px]]
[[Image:Postptms.png|center|600px]]
-
Multiple types, numbers, and combinations of PTMs can occur on the histone tails of the nucleosome at any given time. PTMs can serve as docking sites for protein effectors, which impact chromatin structure and gene expression(24,25). Methylation, phosphorylation, and acetylation have been the most well characterized. Methylation modifications provide a platform for regulatory factors associated with gene activation or repression, depending on the modified residue. Phosphorylation ensures proper chromatin compactio during meiosis and mitosis, as well as defining the site of DNA damage. Acetylation neutralizes the positive charge on lysine and arginine residues, loosening histone:DNA packing, for active gene expression. These positively charged lysine residues are found on the tails of histone proteins, and once acetylated, the positive charge the lysine residue carries is removed, which can loosen the DNA compaction around the central octamer of histone proteins and expose a target gene on the DNA make it more amenable to transcription factors.
+
Multiple types, numbers, and combinations of PTMs can occur on the histone tails of the nucleosome at any given time. PTMs can serve as docking sites for protein effectors, which impact chromatin structure and gene expression<ref>PMID:10638745</ref><ref>PMID:18552846</ref>. Methylation, phosphorylation, and acetylation have been the most well characterized. Methylation modifications provide a platform for regulatory factors associated with gene activation or repression, depending on the modified residue. Phosphorylation ensures proper chromatin compactio during meiosis and mitosis, as well as defining the site of DNA damage. Acetylation neutralizes the positive charge on lysine and arginine residues, loosening histone:DNA packing, for active gene expression. These positively charged lysine residues are found on the tails of histone proteins, and once acetylated, the positive charge the lysine residue carries is removed, which can loosen the DNA compaction around the central octamer of histone proteins and expose a target gene on the DNA make it more amenable to transcription factors.
{|
{|
Line 39: Line 39:
'''The ''<font color='gray'>bromodomain</font>'' function is conserved'''
'''The ''<font color='gray'>bromodomain</font>'' function is conserved'''
-
The only known function of the <font color='gray'>bromodomain</font> is to bind to acetylated lysine residues. This <font color='gray'>bromodomain</font> function is highly conserved throughout evolution and across 42 <font color='gray'>bromodomain</font>-containing proteins. <font color='gray'>Bromodomains</font> can also serve as a site to recruit transcriptional machinery to the target gene once accessible, thus having the power to impact gene expression. <font color='gray'>Bromodomains</font> have been known about since the 1990s, and in 2012, Filippakopoulos, et al. characterized and divided these <font color='gray'>bromodomains</font> into eight sub-families based upon similarities in sequence and structure (PF). Despite <font color='gray'>bromodomains</font> having the same distinct structural fold, the sequences between <font color='gray'>bromodomains</font> both within and across the different subfamilies, varies greatly. The ATAD2B <font color='gray'>bromodomain</font> is able to recognize acetylated lysine modifications on histone proteins (see below)(fillikapolous). The <font color='gray'>bromodomain</font> is the only ATAD2B domain that has been studied, and only little information has been elucidated.
+
The only known function of the <font color='gray'>bromodomain</font> is to bind to acetylated lysine residues. This <font color='gray'>bromodomain</font> function is highly conserved throughout evolution and across 42 <font color='gray'>bromodomain</font>-containing proteins. <font color='gray'>Bromodomains</font> can also serve as a site to recruit transcriptional machinery to the target gene once accessible, thus having the power to impact gene expression. <font color='gray'>Bromodomains</font> have been known about since the 1990s, and in 2012, Filippakopoulos, et al. characterized and divided these <font color='gray'>bromodomains</font> into eight sub-families based upon similarities in sequence and structure <ref>PMID:22464331</ref>. Despite <font color='gray'>bromodomains</font> having the same distinct structural fold, the sequences between <font color='gray'>bromodomains</font> both within and across the different subfamilies, varies greatly. The ATAD2B <font color='gray'>bromodomain</font> is able to recognize acetylated lysine modifications on histone proteins (see below) <ref>PMID:22464331</ref>. The <font color='gray'>bromodomain</font> is the only ATAD2B domain that has been studied, and only little information has been elucidated.
{|
{|
| [[Image:FamilyTrees.png|thumb|left|Phylogenetic tree comparing bromodomain-containing proteins in Family IV to the well characterized BET family of bromodomains|400px]]
| [[Image:FamilyTrees.png|thumb|left|Phylogenetic tree comparing bromodomain-containing proteins in Family IV to the well characterized BET family of bromodomains|400px]]
Line 50: Line 50:
All <font color='gray'>bromodomain</font>-containing proteins have the same structural motif. It is a left-handed four alpha-helical bundle. These alpha helices are connected by two different and flexible loops whose sequences are variable when compared to the other <font color='gray'>bromodomain</font> residues, as seen above. These loops are responsible for coordinating the acetylated lysine histone residues to the <font color='gray'>bromodomain</font> binding pocket. The binding pocket itself is hydrophobic, and for ATAD2 and ATAD2B, deep.
All <font color='gray'>bromodomain</font>-containing proteins have the same structural motif. It is a left-handed four alpha-helical bundle. These alpha helices are connected by two different and flexible loops whose sequences are variable when compared to the other <font color='gray'>bromodomain</font> residues, as seen above. These loops are responsible for coordinating the acetylated lysine histone residues to the <font color='gray'>bromodomain</font> binding pocket. The binding pocket itself is hydrophobic, and for ATAD2 and ATAD2B, deep.
-
The <scene name='90/909366/Atad2histonebinding/2'>conserved asparagine</scene> is the single most important residue for <font color='gray'>bromodomain</font> binding to acetylated lysine residues. Other residues that have been conserved throughout evolution, such as the preceding <scene name='90/909366/Atad2histonebinding/3'>tyrosine</scene> residue, are important for binding to the backbone of the histone tail. This works to help stabilize the acetylated lysine residue insertion into the <font color='gray'>bromodomain</font> binding pocket. Additionally, there is a hydrophobic <scene name='90/909366/Atad2histonebinding/5'>gatekeeper</scene> residue that serves to limit the number of acetylated lysine residues that are inserted into the binding pocket. Another motif in ATAD2 and other <font color='gray'>bromodomains</font>, termed the "RVF" or "WPF" shelf also helps in ligand specificity in the ZA loop. ATAD2B has an "NIF" motif, which also helps it to distinguish between different histone ligands in Lloyd, et al. (2020) LLOYD. Interestingly, both ATAD2 and ATAD2B are known to recognize di-acetylated lysine residues on histone tails, but a structure of this interaction has yet to be solved. Unfortunately due to this, we are unable to visualize how both acetylated lysine residues fit in the binding pocket.
+
The <scene name='90/909366/Atad2histonebinding/2'>conserved asparagine</scene> is the single most important residue for <font color='gray'>bromodomain</font> binding to acetylated lysine residues. Other residues that have been conserved throughout evolution, such as the preceding <scene name='90/909366/Atad2histonebinding/3'>tyrosine</scene> residue, are important for binding to the backbone of the histone tail. This works to help stabilize the acetylated lysine residue insertion into the <font color='gray'>bromodomain</font> binding pocket. Additionally, there is a hydrophobic <scene name='90/909366/Atad2histonebinding/5'>gatekeeper</scene> residue that serves to limit the number of acetylated lysine residues that are inserted into the binding pocket. Another motif in ATAD2 and other <font color='gray'>bromodomains</font>, termed the "RVF" or "WPF" shelf also helps in ligand specificity in the ZA loop. ATAD2B has an "NIF" motif, which also helps it to distinguish between different histone ligands in Lloyd, et al. (2020)<ref>PMID:33084328</ref>. Interestingly, both ATAD2 and ATAD2B are known to recognize di-acetylated lysine residues on histone tails, but a structure of this interaction has yet to be solved. Unfortunately due to this, we are unable to visualize how both acetylated lysine residues fit in the binding pocket.
===<font color='gray'>Bromodomain</font> & ATAD2B Function===
===<font color='gray'>Bromodomain</font> & ATAD2B Function===
[[Image:Ligandtable.png|thumb|right|300px|Binding affinities for the ATAD2B <font color='gray'>bromodomain</font> with histone ligands]]
[[Image:Ligandtable.png|thumb|right|300px|Binding affinities for the ATAD2B <font color='gray'>bromodomain</font> with histone ligands]]
-
Even though a structure doesn't exist with a ligand bound for ATAD2B, <scene name='90/909366/Bindingpocket/3'>important binding site residues</scene> still coordinate interactions with the histone tails (Table). There is only one published manuscript detailing the histone binding partners for the ATAD2B <font color='gray'>bromodomain</font>. The <font color='gray'>bromodomain</font> was able to distinguish between singly-acetylated lysine residues and di-acetylated lysine residues. When histone protein 4 (H4) was acetylated at lysine 5 (K5ac), the binding affinity was the tightest, at 5.2 µM and the weakest for H4K8ac at 1,164.2 µM. The ATAD2B <font color='gray'>bromodomain</font> displays a 223-fold preference for the H4K5ac residue. ATAD2B also prefers the diacetylated ligand H4K5acK12ac, with a binding affinity of 18.7 µM, with 1.5-fold tighter binding than the next preferred residue H4K5acK8ac at 28.1 µM. ATAD2 also exhibits this same preference between these histone ligands. Interestingly, Koo, et al. showed that the ATAD2 <font color='gray'>bromodomain</font> recognizes that di-acetylated lysine modification (H4K5acK12ac) on nascent, or newly formed chromatin. Through recognition of the H4K5acK12ac modification on nascent chromatin/newly formed histones, ATAD2 is recruited to replication sites during chromatin organization and assembly. Even though the biological function of ATAD2 has never been fully elucidated, this manuscript brings a certain insight into its role in chromatin remodeling. While individual domains were not investigated ''in vitro'', ''in vivo'' work displayed that when the AAA <font color='gold'>ATPase</font> 1 domain and <font color='gray'>bromodomain</font> was mutated, their ability to be replicated to nascent chromatin was lost. It is still unclear what specific role each domain has to play in ATAD2 function. ATAD2B has not been investigated ''in vivo'', so it is yet to be determined if it is also replicated to newly synthesized histones. It is interesting that the acetylated lysine recognition trend is the same between the paralogs of ATAD2 and ATAD2B, but it is too soon to say if their functions are the same as well.
+
Even though a structure doesn't exist with a ligand bound for ATAD2B, <scene name='90/909366/Bindingpocket/3'>important binding site residues</scene> still coordinate interactions with the histone tails (Table). There is only one published manuscript detailing the histone binding partners for the ATAD2B <font color='gray'>bromodomain</font>. The <font color='gray'>bromodomain</font> was able to distinguish between singly-acetylated lysine residues and di-acetylated lysine residues. When histone protein 4 (H4) was acetylated at lysine 5 (K5ac), the binding affinity was the tightest, at 5.2 µM and the weakest for H4K8ac at 1,164.2 µM. The ATAD2B <font color='gray'>bromodomain</font> displays a 223-fold preference for the H4K5ac residue. ATAD2B also prefers the diacetylated ligand H4K5acK12ac, with a binding affinity of 18.7 µM, with 1.5-fold tighter binding than the next preferred residue H4K5acK8ac at 28.1 µM. ATAD2 also exhibits this same preference between these histone ligands. Interestingly, Koo, et al.<ref>PMID:27612420</ref> showed that the ATAD2 <font color='gray'>bromodomain</font> recognizes that di-acetylated lysine modification (H4K5acK12ac) on nascent, or newly formed chromatin. Through recognition of the H4K5acK12ac modification on nascent chromatin/newly formed histones, ATAD2 is recruited to replication sites during chromatin organization and assembly. Even though the biological function of ATAD2 has never been fully elucidated, this manuscript brings a certain insight into its role in chromatin remodeling. While individual domains were not investigated ''in vitro'', ''in vivo'' work displayed that when the AAA <font color='gold'>ATPase</font> 1 domain and <font color='gray'>bromodomain</font> was mutated, their ability to be replicated to nascent chromatin was lost. It is still unclear what specific role each domain has to play in ATAD2 function. ATAD2B has not been investigated ''in vivo'', so it is yet to be determined if it is also replicated to newly synthesized histones. It is interesting that the acetylated lysine recognition trend is the same between the paralogs of ATAD2 and ATAD2B, but it is too soon to say if their functions are the same as well.
-
In Lloyd, et al., it was shown that mutation of the conserved asparagine residue (N1031A) severely weakened binding affinity to previously identified histone ligands. Mutagenesis of Y1037A, completely abolished binding affinity to previously identified histone ligand binding partners. Residues in the binding pocket of <font color='gray'>bromodomains</font>, especially the ATAD2B <font color='gray'>bromodomain</font>, are evolutionarily conserved and extremely important for interaction with the acetylated lysine histone ligands.
+
In Lloyd, et al.,<ref>PMID:33084328</ref> it was shown that mutation of the conserved asparagine residue (N1031A) severely weakened binding affinity to previously identified histone ligands. Mutagenesis of Y1037A, completely abolished binding affinity to previously identified histone ligand binding partners. Residues in the binding pocket of <font color='gray'>bromodomains</font>, especially the ATAD2B <font color='gray'>bromodomain</font>, are evolutionarily conserved and extremely important for interaction with the acetylated lysine histone ligands.
===Detailed ATAD2/B <font color='gray'>Bromodomain</font> Structure===
===Detailed ATAD2/B <font color='gray'>Bromodomain</font> Structure===
Line 85: Line 85:
===Domain Function===
===Domain Function===
-
ATAD2 and ATAD2B are chromatin associated proteins (CAPs). Both the ATAD2 and ATAD2B proteins contain two conserved domains that can interact with chromatin: an ''AAA <font color='gold'>ATPase</font> domain'' and a ''<font color='gray'>bromodomain</font>''<ref>PMID:22464331</ref>. Additionally, there are linker regions and a C-terminal domain, as represented by the AlphaFold-predicted structure. ATAD2 is a large protein (1,390 amino acids & 158.6 kDa) and has been studied primarily using cellular assays. In these assays, when both AAA <font color='gold'>ATPase</font> and the <font color='gray'>bromodomain</font> are present, ATAD2 has a tighter affinity for chromatin, which suggests both are important for the formation of regulatory chromatin complexes(10,4). <font color='gold'>ATPase</font> domains are known to promote the assembly of coregulator complexes at chromatin, and the ability of the <font color='gray'>bromodomain</font> to recognize certain histone modifications may specify the location of where ATAD2 is recruited on chromatin(38). Additionally, we know that ATAD2 is recruited to newly synthesized histones on nascent chromatin; moreover, ATAD2 is only present during the S-phase of the cell cycle (KOO), where chromatin remodelers are most active. Chromatin remodeler proteins are usually large complexes, and previously, it was determined that ATAD2 can oligomerize, and the first AAA <font color='gold'>ATPase</font> is important for this oligomerization (10). Recently, studies of ATAD2 using the yeast homolog ''Abo1'', discovered that the <font color='gold'>ATPase</font> domains formed a <scene name='90/909366/Abo1/1'>hexamer</scene> (using cryo-EM) and was involved with the loading of H3 and H4 onto the NCP. The C-terminal domain was necessary for hexamer stability. However, the <font color='gray'>bromodomain</font> could not be visualized using cryo-EM. Another yeast homolog, ''Yta7'', found ATAD2 to function as a histone chaperone. The in-depth molecular functions of ATAD2, ''and'' ATAD2B still remain incredible elusive despite recent advances, due to this lack of structural information.
+
ATAD2 and ATAD2B are chromatin associated proteins (CAPs). Both the ATAD2 and ATAD2B proteins contain two conserved domains that can interact with chromatin: an ''AAA <font color='gold'>ATPase</font> domain'' and a ''<font color='gray'>bromodomain</font>''<ref>PMID:22464331</ref>. Additionally, there are linker regions and a C-terminal domain, as represented by the AlphaFold-predicted structure. ATAD2 is a large protein (1,390 amino acids & 158.6 kDa) and has been studied primarily using cellular assays. In these assays, when both AAA <font color='gold'>ATPase</font> and the <font color='gray'>bromodomain</font> are present, ATAD2 has a tighter affinity for chromatin, which suggests both are important for the formation of regulatory chromatin complexes<ref>PMID:20581866</ref><ref>PMID:22464331</ref>. <font color='gold'>ATPase</font> domains are known to promote the assembly of coregulator complexes at chromatin, and the ability of the <font color='gray'>bromodomain</font> to recognize certain histone modifications may specify the location of where ATAD2 is recruited on chromatin<ref>PMID:17998543</ref>. Additionally, we know that ATAD2 is recruited to newly synthesized histones on nascent chromatin; moreover, ATAD2 is only present during the S-phase of the cell cycle <ref>PMID:27612420</ref>, where chromatin remodelers are most active. Chromatin remodeler proteins are usually large complexes, and previously, it was determined that ATAD2 can oligomerize, and the first AAA <font color='gold'>ATPase</font> is important for this oligomerization<ref>PMID:20581866</ref>. Recently, studies of ATAD2 using the yeast homolog ''Abo1'', discovered that the <font color='gold'>ATPase</font> domains formed a <scene name='90/909366/Abo1/1'>hexamer</scene> (using cryo-EM) and was involved with the loading of H3 and H4 onto the NCP. The C-terminal domain was necessary for hexamer stability. However, the <font color='gray'>bromodomain</font> could not be visualized using cryo-EM. Another yeast homolog, ''Yta7'', found ATAD2 to function as a histone chaperone. The in-depth molecular functions of ATAD2, ''and'' ATAD2B still remain incredible elusive despite recent advances, due to this lack of structural information.
<font color='gray'>bromodomain</font>
<font color='gray'>bromodomain</font>
Line 97: Line 97:
== Therapeutic Interventions ==
== Therapeutic Interventions ==
-
Many <font color='gray'>bromodomain</font>-containing proteins are highly overexpressed in many forms of cancer, and the pharmaceutical industry is keen to design inhibitors to temper <font color='gray'>bromodomain</font> function in cancer progression. The most well-known inhibitor is a pan-<font color='gray'>bromodomain</font> inhibitor, JQ1 that was originally designed for the BET Family <font color='gray'>bromodomains</font>. Over time, it has been characterized to have slightly inhibitory effects in other <font color='gray'>bromodomains</font>. ATAD2B does not have a specific inhibitor, but ATAD2 has a few currently commercially available. The ATAD2 <font color='gray'>bromodomain</font>, however, is notoriously extremely difficult to drug, due to the deepness of its binding pocket(16). Only a handful of the compounds developed have been shown to be effective in blocking the binding interaction between ATAD2 and acetylated lysine PTMs (16,18,19). Despite ATAD2B not having its own selective inhibitor, Llloyd, et al. characterized the effects of a known ATAD2 inhibitor, Compound 38, with the ATAD2B <font color='gray'>bromodomain</font>.
+
Many <font color='gray'>bromodomain</font>-containing proteins are highly overexpressed in many forms of cancer, and the pharmaceutical industry is keen to design inhibitors to temper <font color='gray'>bromodomain</font> function in cancer progression. The most well-known inhibitor is a pan-<font color='gray'>bromodomain</font> inhibitor, JQ1 that was originally designed for the BET Family <font color='gray'>bromodomains</font>. Over time, it has been characterized to have slightly inhibitory effects in other <font color='gray'>bromodomains</font>. ATAD2B does not have a specific inhibitor, but ATAD2 has a few currently commercially available. The ATAD2 <font color='gray'>bromodomain</font>, however, is notoriously extremely difficult to drug, due to the deepness of its binding pocket<ref>PMID:27530368</ref>. Only a handful of the compounds developed have been shown to be effective in blocking the binding interaction between ATAD2 and acetylated lysine PTMs<ref>PMID:27530368</ref><ref>PMID:26155854</ref><ref>PMID:32174193</ref>. Despite ATAD2B not having its own selective inhibitor, Llloyd, et al.<ref>PMID:33084328</ref> characterized the effects of a known ATAD2 inhibitor, Compound 38, with the ATAD2B <font color='gray'>bromodomain</font>.
===Compound 38===
===Compound 38===
-
Compound 38 (C-38) was 1.8-fold times more selective for the ATAD2 <font color='gray'>bromodomain</font> than ATAD2B, with 90 nM and 166.3 nM binding affinities, respectively. They solved the <scene name='90/909366/C38/1'>structure</scene> of C-38 bound to the ATAD2B <font color='gray'>bromodomain</font> to determine the specific molecular interactions that are occurring (PDB ID: 6VEO). C-38 was coordinated in the binding pocket much like the acetylated lysine residues of the histone proteins: through hydrogen bonds and hydrophobic interactions. The inhibitor bound to the conserved asparagine (N1038), and was coordinated through hydrophobic interactions with the gatekeeper residue I1048. However, since this compound was manufactured to be specific for the ATAD2 <font color='gray'>bromodomain</font>, some important interactions between protein and inhibitor are not present in the ATAD2B <font color='gray'>bromodomain</font> structure, including an important hydrogen bond interaction. These mechanistic molecular differences are thought to play a role in the lower affinity for C-38 with ATAD2B. Overall, however, the coordination of C-38 between ATAD2 and ATAD2B is extremely similar, and Lloyd, et al. postulates that it may be difficult to develop a truly selective inhibitor for each protein. This endeavor is still being explored.
+
Compound 38 (C-38) was 1.8-fold times more selective for the ATAD2 <font color='gray'>bromodomain</font> than ATAD2B, with 90 nM and 166.3 nM binding affinities, respectively. They solved the <scene name='90/909366/C38/1'>structure</scene> of C-38 bound to the ATAD2B <font color='gray'>bromodomain</font> to determine the specific molecular interactions that are occurring (PDB ID: 6VEO). C-38 was coordinated in the binding pocket much like the acetylated lysine residues of the histone proteins: through hydrogen bonds and hydrophobic interactions. The inhibitor bound to the conserved asparagine (N1038), and was coordinated through hydrophobic interactions with the gatekeeper residue I1048. However, since this compound was manufactured to be specific for the ATAD2 <font color='gray'>bromodomain</font>, some important interactions between protein and inhibitor are not present in the ATAD2B <font color='gray'>bromodomain</font> structure, including an important hydrogen bond interaction. These mechanistic molecular differences are thought to play a role in the lower affinity for C-38 with ATAD2B. Overall, however, the coordination of C-38 between ATAD2 and ATAD2B is extremely similar, and Lloyd, et al.<ref>PMID:33084328</ref> postulates that it may be difficult to develop a truly selective inhibitor for each protein. This endeavor is still being explored.
==Additional Resources==
==Additional Resources==
Line 114: Line 114:
==Acknowledgments==
==Acknowledgments==
[https://www.med.uvm.edu/pharmacology/glass_lab Glass] & [https://www.uvm.edu/cnhs/bhsc/profiles/seth-frietze-phd Frietze Laboratories] : UVM researchers working on learning more about the function of ATAD2, and especially ATAD2B!
[https://www.med.uvm.edu/pharmacology/glass_lab Glass] & [https://www.uvm.edu/cnhs/bhsc/profiles/seth-frietze-phd Frietze Laboratories] : UVM researchers working on learning more about the function of ATAD2, and especially ATAD2B!
 +
Images created with BioRender.com & PyMOL Molecular Graphics System
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Revision as of 02:25, 2 May 2022

The ATPase Family, AAA Domain-Containing Protein 2B (ATAD2B)

Important

Drag the structure with the mouse to rotate

References

  1. Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010 Dec;52(9):747-55. doi: 10.1111/j.1440-169X.2010.01211.x. PMID:21158754 doi:http://dx.doi.org/10.1111/j.1440-169X.2010.01211.x
  2. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010 Sep 16;29(37):5171-81. doi: 10.1038/onc.2010.259. Epub 2010 Jun, 28. PMID:20581866 doi:http://dx.doi.org/10.1038/onc.2010.259
  3. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010 Nov 15;70(22):9402-12. doi: 10.1158/0008-5472.CAN-10-1199. Epub , 2010 Sep 23. PMID:20864510 doi:http://dx.doi.org/10.1158/0008-5472.CAN-10-1199
  4. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009 Nov 1;69(21):8491-8. doi: 10.1158/0008-5472.CAN-09-2131. Epub, 2009 Oct 20. PMID:19843847 doi:http://dx.doi.org/10.1158/0008-5472.CAN-09-2131
  5. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009 Nov 1;69(21):8491-8. doi: 10.1158/0008-5472.CAN-09-2131. Epub, 2009 Oct 20. PMID:19843847 doi:http://dx.doi.org/10.1158/0008-5472.CAN-09-2131
  6. Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010 Dec;52(9):747-55. doi: 10.1111/j.1440-169X.2010.01211.x. PMID:21158754 doi:http://dx.doi.org/10.1111/j.1440-169X.2010.01211.x
  7. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178
  8. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012 Mar 30;149(1):214-31. PMID:22464331 doi:10.1016/j.cell.2012.02.013
  9. Mujtaba S, Zeng L, Zhou MM. Structure and acetyl-lysine recognition of the bromodomain. Oncogene. 2007 Aug 13;26(37):5521-7. doi: 10.1038/sj.onc.1210618. PMID:17694091 doi:http://dx.doi.org/10.1038/sj.onc.1210618
  10. Evans CM, Phillips M, Malone KL, Tonelli M, Cornilescu G, Cornilescu C, Holton SJ, Gorjanacz M, Wang L, Carlson S, Gay JC, Nix JC, Demeler B, Markley JL, Glass KC. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain. Int J Mol Sci. 2021 Aug 24;22(17). pii: ijms22179128. doi: 10.3390/ijms22179128. PMID:34502039 doi:http://dx.doi.org/10.3390/ijms22179128
  11. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178
  12. Cho C, Jang J, Kang Y, Watanabe H, Uchihashi T, Kim SJ, Kato K, Lee JY, Song JJ. Structural basis of nucleosome assembly by the Abo1 AAA+ ATPase histone chaperone. Nat Commun. 2019 Dec 17;10(1):5764. doi: 10.1038/s41467-019-13743-9. PMID:31848341 doi:http://dx.doi.org/10.1038/s41467-019-13743-9
  13. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999 Oct 15;286(5439):481-6. doi: 10.1126/science.286.5439.481. PMID:10521337 doi:http://dx.doi.org/10.1126/science.286.5439.481
  14. Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. Nature. 2019 Jul;571(7766):489-499. doi: 10.1038/s41586-019-1411-0. Epub 2019 Jul, 24. PMID:31341302 doi:http://dx.doi.org/10.1038/s41586-019-1411-0
  15. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000 Jan 6;403(6765):41-5. doi: 10.1038/47412. PMID:10638745 doi:http://dx.doi.org/10.1038/47412
  16. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997 Sep 18;389(6648):251-60. PMID:9305837 doi:10.1038/38444
  17. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000 Jan 6;403(6765):41-5. doi: 10.1038/47412. PMID:10638745 doi:http://dx.doi.org/10.1038/47412
  18. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008 Jul;40(7):897-903. doi: 10.1038/ng.154. Epub 2008 Jun 15. PMID:18552846 doi:http://dx.doi.org/10.1038/ng.154
  19. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012 Mar 30;149(1):214-31. PMID:22464331 doi:10.1016/j.cell.2012.02.013
  20. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012 Mar 30;149(1):214-31. PMID:22464331 doi:10.1016/j.cell.2012.02.013
  21. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178
  22. Koo SJ, Fernandez-Montalvan AE, Badock V, Ott CJ, Holton SJ, von Ahsen O, Toedling J, Vittori S, Bradner JE, Gorjanacz M. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget. 2016 Oct 25;7(43):70323-70335. doi: 10.18632/oncotarget.11855. PMID:27612420 doi:http://dx.doi.org/10.18632/oncotarget.11855
  23. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178
  24. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature. 2021 Jul 15. pii: 10.1038/s41586-021-03819-2. doi:, 10.1038/s41586-021-03819-2. PMID:34265844 doi:http://dx.doi.org/10.1038/s41586-021-03819-2
  25. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, Zidek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R, Vora A, Lutfi M, Figurnov M, Cowie A, Hobbs N, Kohli P, Kleywegt G, Birney E, Hassabis D, Velankar S. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444. doi: 10.1093/nar/gkab1061. PMID:34791371 doi:http://dx.doi.org/10.1093/nar/gkab1061
  26. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012 Mar 30;149(1):214-31. PMID:22464331 doi:10.1016/j.cell.2012.02.013
  27. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010 Sep 16;29(37):5171-81. doi: 10.1038/onc.2010.259. Epub 2010 Jun, 28. PMID:20581866 doi:http://dx.doi.org/10.1038/onc.2010.259
  28. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012 Mar 30;149(1):214-31. PMID:22464331 doi:10.1016/j.cell.2012.02.013
  29. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18067-72. Epub 2007 Nov 12. PMID:17998543 doi:http://dx.doi.org/10.1073/pnas.0705814104
  30. Koo SJ, Fernandez-Montalvan AE, Badock V, Ott CJ, Holton SJ, von Ahsen O, Toedling J, Vittori S, Bradner JE, Gorjanacz M. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget. 2016 Oct 25;7(43):70323-70335. doi: 10.18632/oncotarget.11855. PMID:27612420 doi:http://dx.doi.org/10.18632/oncotarget.11855
  31. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010 Sep 16;29(37):5171-81. doi: 10.1038/onc.2010.259. Epub 2010 Jun, 28. PMID:20581866 doi:http://dx.doi.org/10.1038/onc.2010.259
  32. Bamborough P, Chung CW, Demont EH, Furze RC, Bannister AJ, Che KH, Diallo H, Douault C, Grandi P, Kouzarides T, Michon AM, Mitchell DJ, Prinjha RK, Rau C, Robson S, Sheppard RJ, Upton R, Watson RJ. A Chemical Probe for the ATAD2 Bromodomain. Angew Chem Int Ed Engl. 2016 Sep 12;55(38):11382-6. doi: 10.1002/anie.201603928. , Epub 2016 Aug 17. PMID:27530368 doi:http://dx.doi.org/10.1002/anie.201603928
  33. Bamborough P, Chung CW, Demont EH, Furze RC, Bannister AJ, Che KH, Diallo H, Douault C, Grandi P, Kouzarides T, Michon AM, Mitchell DJ, Prinjha RK, Rau C, Robson S, Sheppard RJ, Upton R, Watson RJ. A Chemical Probe for the ATAD2 Bromodomain. Angew Chem Int Ed Engl. 2016 Sep 12;55(38):11382-6. doi: 10.1002/anie.201603928. , Epub 2016 Aug 17. PMID:27530368 doi:http://dx.doi.org/10.1002/anie.201603928
  34. Demont EH, Chung CW, Furze RC, Grandi P, Michon AM, Wellaway C, Barrett N, Bridges AM, Craggs PD, Diallo H, Dixon DP, Douault C, Emmons AJ, Jones EJ, Karamshi BV, Locke K, Mitchell DJ, Mouzon BH, Prinjha RK, Roberts AD, Sheppard RJ, Watson RJ, Bamborough P. Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 9. PMID:26155854 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b00772
  35. Yao D, Zhang J, Wang J, Pan D, He Z. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening. J Enzyme Inhib Med Chem. 2020 Dec;35(1):713-725. doi:, 10.1080/14756366.2020.1740924. PMID:32174193 doi:http://dx.doi.org/10.1080/14756366.2020.1740924
  36. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178
  37. Lloyd JT, McLaughlin K, Lubula MY, Gay JC, Dest A, Gao C, Phillips M, Tonelli M, Cornilescu G, Marunde MR, Evans CM, Boyson SP, Carlson S, Keogh MC, Markley JL, Frietze S, Glass KC. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J Med Chem. 2020 Oct 21. doi: 10.1021/acs.jmedchem.0c01178. PMID:33084328 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c01178

Proteopedia Page Contributors and Editors (what is this?)

Kiera Malone

Personal tools